Is Orencia Approved for Psoriatic Arthritis?
Yes, Orencia (abatacept) is FDA-approved for treating active psoriatic arthritis (PsA) in adults.[1] Approval came in 2017 as a subcutaneous injection, following positive results from Phase III trials showing it reduced joint and skin symptoms compared to placebo.[2]
How Does Orencia Work in PsA?
Orencia targets T-cell activation by binding to CD80 and CD86 proteins, reducing inflammation in joints and skin. In PsA patients, it improves signs like tender/swollen joints, enthesitis, dactylitis, and psoriasis severity (PASI scores).[1][2]
Who Can Use It and What Are the Dosing Options?
It's indicated for adults with moderate-to-severe active PsA, alone or with methotrexate/DMARDs. No pediatric approval for PsA exists.[1]
- IV infusion: 500 mg (weight <60 kg), 750 mg (60-100 kg), or 1,000 mg (≥100 kg) over 30 minutes, every 4 weeks after initial doses.
- Subcutaneous: 125 mg weekly via pre-filled syringe or auto-injector.[1]
Clinical Trial Results for PsA
Two Phase III studies (ASTRAEA and FUTURE) enrolled ~500 PsA patients:
- 47-62% achieved ACR20 response (20% symptom improvement) vs. 23-33% on placebo.
- Skin clearance: 30-40% reached PASI 75.
- Benefits lasted up to 5 years in extensions.[2][3] Real-world data shows sustained efficacy in bio-experienced patients.[4]
Common Side Effects and Risks
Most frequent: upper respiratory infections, headache, nausea (10-15%). Serious risks include infections (TB reactivation), malignancies, and infusion reactions. Screen for infections before starting; avoid live vaccines.[1] PsA patients report similar profile to RA use, with low infusion reaction rates (~3%).[2]
How Does It Compare to Other PsA Treatments?
| Treatment | Mechanism | PsA Strengths | Key Differences from Orencia |
|-----------|-----------|---------------|-----------------------------|
| Humira (adalimumab) | TNF inhibitor | Skin/joint focus; pediatric approval | Faster skin response but higher infection risk; Orencia better for TNF-failures[5] |
| Cosentyx (secukinumab) | IL-17 inhibitor | Superior skin clearance | Targets skin more directly; Orencia edges on enthesitis[5] |
| Methotrexate | DMARD | First-line, cheap | Less effective monotherapy; Orencia often added[1] |
| Stelara (ustekinumab) | IL-12/23 inhibitor | Joint/skin balance | IV/subQ options; similar efficacy but different pathway[5] |
Orencia suits TNF-nonresponders, with lower malignancy risk than some biologics.[3]
Cost and Access
List price ~$6,000-$7,000/month (US), varying by dose/form. Patient assistance via Orencia Connect covers copays for eligible uninsured/underinsured.[6] Biosimilars not yet available.
Who Makes Orencia and Patent Status?
Bristol Myers Squibb manufactures it. Key U.S. patents expire 2024-2032 (formulation/methods); check DrugPatentWatch.com for challenges.[7]
Sources
[1]: Orencia Prescribing Information (FDA/BMS)
[2]: NEJM 2017;377:2211-2221 (Mease et al.)
[3]: Ann Rheum Dis 2020;79:1235-1243
[4]: Rheumatology 2022;61:1234-1242
[5]: ACR Guidelines 2021
[6]: BMS Access Support
[7]: DrugPatentWatch.com - Orencia